BONK, INC. current report, 16 April 2021

Full document

Filing Summary

Important filing identification: The supplied filing text is for Jupiter Wellness, Inc., not BONK, Inc. The report is a Form 8-K filed April 16, 2021, under Section 13 or 15(d) of the Exchange Act.

Business Context and Reporting Period

  • Jupiter Wellness, Inc. is incorporated in Delaware and traded common stock under the symbol JUPW and warrants under JUPWW on Nasdaq.
  • The filing reports corporate officer appointments and related Regulation FD disclosure. It does not provide financial statements or results for a reporting period.
  • The company identified itself as an emerging growth company.

Management Changes

  • Dr. Glynn Wilson was appointed Chief Science Officer while continuing as Chairman of the Board. He previously led research and development.
  • Rich Miller was appointed Chief Compliance Officer while continuing as a director. This was described as a newly created position.
  • Ryan Allison was appointed Chief Operating Officer. He previously served as Director and Vice President of Business Development.

Financial Metrics and Liquidity

The filing text does not provide clear values for revenue, profit or loss, cash flow, margins, debt, cash balances, liquidity, capital expenditures, or other financial metrics.

Outlook, Risks, and Unusual Items

  • The company issued a press release dated April 16, 2021 as Exhibit 99.1 and incorporated it by reference; the supplied text does not include the press release contents.
  • No guidance, forecast, material contingency, litigation update, financing arrangement, or other unusual financial item is described in the provided filing text.
  • The officer changes may indicate increased emphasis on scientific development, compliance, and operations, but the filing does not quantify their expected financial impact.

Key Investor Verification Items

  1. Confirm the intended issuer, because the request identifies BONK, Inc. while the filing identifies Jupiter Wellness, Inc.
  2. Review Exhibit 99.1 for the company’s related announcement and any additional business or outlook information.
  3. Review the company’s contemporaneous periodic filings for financial performance, liquidity, debt, and risk disclosures.
  4. Assess whether the newly created compliance role and management transitions affect governance, operations, or execution risk.